RESUMEN
Our study investigated the relationship between gastric cancer development and activity of Helicobacter pylori-associated chronic gastritis or the resulting chronic atrophic gastritis (CAG). A cohort of 4,655 healthy asymptomatic subjects, in whom serum pepsinogen (PG) and H. pylori antibody titer had been measured to assess the activity and stage of H. pylori-associated chronic gastritis, was followed for up to 16 years, and cancer development was investigated. In subjects with a serologically diagnosed healthy stomach (H. pylori-negative/CAG-negative), cancer incidence rate was low, at 16/100,000 person-years. With the establishment of H. pylori infection and progression of chronic gastritis, significant stepwise cancer risk elevations were seen from CAG-free subjects (H. pylori-positive/CAG-negative) [hazard ratio (HR) = 8.9, 95% confidence interval (CI) = 2.7-54.7] to subjects with CAG (H. pylori-positive/CAG-positive) (HR = 17.7, 95% CI = 5.4-108.6) and finally to subjects with metaplastic gastritis (H. pylori-negative/CAG-positive) (HR = 69.7, 95% CI = 13.6-502.9). In H. pylori-infected CAG-free subjects, significantly elevated cancer risk was observed in the subgroup with active inflammation-based high PG II level or potent immune response-based high H. pylori antibody titer; the former was associated with a particularly high risk of diffuse-type cancer, and both subgroups showed high cancer incidence rates of around 250/100,000 person-years, comparable to that in subjects with CAG. No such risk elevation was observed in H. pylori-infected subjects with CAG. These results clearly indicate that gastric cancer develops mainly from the gastritis-atrophy-metaplasia-cancer sequence and partly from active inflammation-based direct carcinogenesis, and that serum levels of PG and H. pylori antibody titer provide indices of cancer development in H. pylori-infected subjects.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Gastritis Atrófica/diagnóstico , Infecciones por Helicobacter/complicaciones , Inflamación/diagnóstico , Pepsinógeno A/sangre , Pepsinógeno C/sangre , Neoplasias Gástricas/diagnóstico , Anticuerpos Antibacterianos/inmunología , Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/inmunología , Estudios de Cohortes , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Estudios de Seguimiento , Gastritis Atrófica/sangre , Gastritis Atrófica/etiología , Infecciones por Helicobacter/inmunología , Infecciones por Helicobacter/microbiología , Helicobacter pylori/inmunología , Helicobacter pylori/patogenicidad , Humanos , Inflamación/sangre , Inflamación/etiología , Masculino , Metaplasia/sangre , Metaplasia/diagnóstico , Metaplasia/etiología , Persona de Mediana Edad , Pronóstico , Radioinmunoensayo , Factores de Riesgo , Estómago/patología , Estómago/virología , Neoplasias Gástricas/sangre , Neoplasias Gástricas/etiologíaRESUMEN
OBJECTIVES: The goal of this cross-sectional study was to assess whether habitual coffee consumption shows beneficial association with metabolic syndrome (MetS) in adults. METHODS: The association of coffee consumption and MetS-related biomarkers including visceral fat area (VFA) and subcutaneous fat area (SFA), total serum adiponectin (T-Ad), low-molecular-weight serum adiponectin (LMW-AD), medium-molecular-weight serum adiponectin (MMW-Ad), and high-molecular-weight serum adiponectin (HMW-Ad) levels were analyzed among 364 Japanese men (36-61 y old) using two models of multivariate regression analyses; model 1 (adjusted for age, alcohol drinking, smoking, and walking status) and model 2 (adjusted for body mass index in addition to model 1 analysis). Participants were categorized into two groups according to their MetS risk score (raised blood pressure and hemoglobin A1c levels, and reduced high-density lipoprotein cholesterol levels). RESULTS: Both light (1-3 cups/d) and moderate (≥4 cups/d) coffee consumption showed significant inverse associations with VFA and VFA/SFA ratio (P < 0.0001). Moderate coffee consumption showed a favorable tendency toward these associations with T-Ad (P = 0.06) and HMW-Ad (P = 0.07) levels in model 1 analysis. In participants with lower MetS risk score (≤1), moderate coffee consumption showed significant associations with T-Ad and HMW-Ad levels (P < 0.05) in both analyses, whereas no significant associations of coffee consumption with adiponectin levels were seen in the men with higher MetS risk scores (≥2). CONCLUSIONS: Habitual moderate coffee consumption shows significant inverse associations with MetS-related biomarkers possibly involving adiponectin, which is inversely related to visceral fat accumulation.
Asunto(s)
Adiponectina/sangre , Biomarcadores/sangre , Café , Síndrome Metabólico/sangre , Adulto , Índice de Masa Corporal , Colesterol/sangre , Estudios Transversales , Conducta Alimentaria , Hemoglobina Glucada/metabolismo , Humanos , Grasa Intraabdominal/metabolismo , Masculino , Persona de Mediana Edad , Peso Molecular , Análisis Multivariante , Análisis de Regresión , Factores de Riesgo , Grasa Subcutánea/metabolismoRESUMEN
AIM: Although frequent vomiting reflexes during esophagogastroduodenoscopy (EGD) causes suffering in patients, very few studies have investigated the characteristics of subjects who frequently develop vomiting reflexes. This study examined the incidence of the vomiting reflex and related factors, especially upper gastrointestinal symptoms, among individuals undergoing transoral EGD. METHODS: Subjects included 488 consecutive adults (mean age, 56.1 ± 8.9 years) who underwent transoral EGD for gastric cancer screening between February 2010 and March 2011. All procedures were performed by an endoscopist with 15 years of experience. Based on a questionnaire survey using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG), symptoms (dyspepsia and acid reflux symptoms) and the number of vomiting reflexes during EGD were recorded. RESULTS: Of the 488 subjects, 271 (56%) developed vomiting reflexes (mean, 4.2 times). This reflex-positive group was younger (54.3 ± 9.5 years) than the reflex-negative group (58.3 ± 7.7 years, P < 0.001). The number of subjects in the reflex-positive group with a high FSSG dyspepsia score (2.27 ± 2.57 vs 1.23 ± 1.84; P < 0.001), acid reflux symptom score (1.96 ± 2.22 vs 1.34 ± 2.14; P < 0.01) or an esophageal hiatal hernia (14.8% vs 4.6%; P < 0.001) was significantly higher than in the reflex-negative group. Multivariate analysis also showed a significant correlation between these four factors and the occurrence of vomiting reflexes. Using an FSSG dyspepsia score of 1 as the cut-off offered 68% sensitivity and 57% specificity for predicting the occurrence of vomiting reflexes. CONCLUSION: Based on FSSG questionnaire responses on upper gastrointestinal symptoms, dyspepsia symptoms, in particular, are related to presence of vomiting reflexes during EGD.
Asunto(s)
Dispepsia/etiología , Endoscopía del Sistema Digestivo , Reflejo/fisiología , Vómitos/fisiopatología , Dispepsia/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Neoplasias Gástricas/diagnóstico , Encuestas y Cuestionarios , Vómitos/complicacionesRESUMEN
This study aimed to elucidate groups at high risk of developing cancer among patients with serologically identified Helicobacter pylori infection and nonatrophic stomach. Annual endoscopy was performed for a mean of 5.4 years in 496 asymptomatic middle-aged men who were H. pylori antibody-positive and pepsinogen (PG) test-negative. Subjects were stratified according to the activity of H. pylori-associated gastritis measured by serum levels of PG and H. pylori antibody, and/or by endoscopic findings of rugal hyperplastic gastritis (RHG), and cancer development was investigated. During the study period, seven cases of cancer developed in the cohort (incidence rate, 261/100,000 person-years), with 85.7% developing in the group showing a PGI/II ratio ≤ 3.0, reflecting active inflammation-based high PGII levels. Cancer incidence was significantly higher in this group (750/100,000 person-years) than in groups with less active gastritis. Furthermore, cancer incidence for this group was significantly higher in the subgroup with high H. pylori antibody titers than in the low-titer subgroup. Meanwhile, endoscopic findings revealed that 11.7% of subjects showed RHG reflecting localized highly active inflammation, and cancer risk was significantly higher in patients with RHG than in patients without. Combining the two serum tests and endoscopic examination for RHG allowed identification of subjects with more active gastritis and higher cancer risk. No cancer development was observed in these high-risk subjects after H. pylori eradication. Subjects with highly active gastritis identified by the two serological tests and endoscopic RHG constitute a group at high risk of cancer development with H. pylori-infected nonatrophic stomach.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Gastritis Atrófica/patología , Helicobacter pylori/inmunología , Inflamación/patología , Pepsinógeno A/sangre , Neoplasias Gástricas/sangre , Neoplasias Gástricas/virología , Anticuerpos Antibacterianos/inmunología , Estudios de Cohortes , Endoscopía/métodos , Femenino , Estudios de Seguimiento , Gastritis Atrófica/sangre , Gastritis Atrófica/inmunología , Gastritis Atrófica/virología , Infecciones por Helicobacter/sangre , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/inmunología , Humanos , Hiperplasia/sangre , Hiperplasia/inmunología , Hiperplasia/patología , Incidencia , Inflamación/sangre , Inflamación/inmunología , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Factores de Riesgo , Estómago/microbiología , Estómago/patología , Neoplasias Gástricas/inmunología , Neoplasias Gástricas/patologíaRESUMEN
AIM: To evaluate the association of Helicobacter pylori (H.pylori)-related chronic gastritis stage with upper gastrointestinal symptoms and gastroesophageal reflux disease (GERD). METHODS: Subjects underwent upper gastrointestinal endoscopy, a questionnaire using a frequency scale for symptoms of GERD (FSSG), and measurements of serum H.pylori-antibody and pepsinogen (PG) levels. They were classified into the following 4 groups in terms of H.pylori-related chronic gastritis stage: Group A (n = 219), H.pylori(-)PG(-); Group B (n = 310), H.pylori(+)PG(-); Group C (n = 279), H.pylori(+)PG(+); and Group D (n = 17), H.pylori(-)PG(+). RESULTS: Reflux esophagitis occurred in 30.6% of Group A, 14.5% of Group B, 6.8% of Group C, and 0% of Group D (P < 0.001). Scores for acid reflux symptoms decreased significantly with chronic gastritis stage (from Group A to D) (P < 0.05), while scores for dysmotility symptoms did not differ significantly. The prevalence of non-erosive reflux disease (NERD) did not differ among groups. However, in subjects with GERD, the prevalence of NERD tended to increase with chronic gastritis stage (P = 0.081). CONCLUSION: Acid reflux symptoms and the prevalence of reflux esophagitis can be assessed by measuring both serum H.pylori-antibody and PG levels.
RESUMEN
This study investigated correlations between Helicobacter pylori infection or chronic atrophic gastritis (CAG) and risk of colorectal adenoma in a population-based case-control study. Subjects comprised asymptomatic, middle-aged, male Japanese factory workers who participated in an annual health check-up program, including cancer screening with colonoscopy. We selected 239 colorectal adenoma cases based on histological evaluation and 239 age-matched adenoma-free controls, and evaluated colorectal adenoma risk according to stage of H. pylori-related chronic gastritis as determined by serum tests for H. pylori antibody titer and pepsinogen. Subjects with colorectal adenoma were more likely to be smokers and have hypercholesterolemia. H. pylori infection was a risk factor for adenoma as a whole (crude odds ratio [OR]: 2.26, 95% confidence interval [CI]: 1.44-3.55). Analysis of distal adenoma cases showed that adenoma risk was significantly increased in the presence of H. pylori infection, but there was no further increase in risk with CAG. In contrast, proximal adenoma risk increased stepwise with the presence and progression of H. pylori-related chronic gastritis and showed a maximal and significant increase with CAG (crude OR: 4.51, 95% CI: 1.43-14.2). Subjects with more extensive and severe gastritis showed still higher risk not only for proximal but also for distal adenoma. H. pylori-related chronic gastritis is likely to be involved in the development of colorectal neoplasms, and its progression appears to increase the risk, particularly for proximal adenomas. Knowing the H. pylori-related chronic gastritis stage will probably be useful for evaluation of risk for colorectal neoplasia.
Asunto(s)
Adenocarcinoma/etiología , Adenoma/etiología , Neoplasias Colorrectales/etiología , Gastritis Atrófica/complicaciones , Infecciones por Helicobacter/complicaciones , Helicobacter pylori/patogenicidad , Adenocarcinoma/epidemiología , Adenoma/epidemiología , Adulto , Estudios de Casos y Controles , Estudios de Cohortes , Neoplasias Colorrectales/epidemiología , Estudios de Seguimiento , Gastritis Atrófica/virología , Infecciones por Helicobacter/virología , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Pronóstico , Factores de Riesgo , Encuestas y Cuestionarios , Tasa de SupervivenciaRESUMEN
The present study investigated the preventive effects of etodolac, a selective cyclo-oxygenase (COX)-2 inhibitor, on metachronous cancer development after endoscopic resection of early gastric cancer. Among 267 early gastric cancer patients who underwent endoscopic resection, 47 patients with extensive metaplastic gastritis were selected based on endoscopic findings and our previously described criteria of serum pepsinogen (PG) test-positive and Helicobacter pylori antibody-negative conditions. Nonrandomized etodolac treatment (300 mg/day) was administered to 26 patients (Group A), while the remaining 21 patients were untreated (Group B). No significant differences in age, sex distribution, lifestyle factors or extent of metaplastic gastritis at baseline were identified between groups. Patients were followed for metachronous cancer development with endoscopy every 6-12 months for up to 5 years. Mean (standard deviation) follow-up period was 4.2 (0.9) years. In Group B, 5 cancers developed (incidence rate = 6,266/100,000 person-years), significantly more than the 1 cancer in Group A (incidence rate = 898/100,000 person-years; p < 0.05). Long-term etodolac treatment did not influence the extent of metaplastic gastritis as revealed by endoscopic findings or by serum PG levels, but effectively reduced metachronous cancer development in patients with extensive metaplastic gastritis. These results strongly suggest that chemoprevention of cancer in the metaplastic stomach is possible by controlling COX-2 expression.
Asunto(s)
Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Etodolaco/uso terapéutico , Gastritis/prevención & control , Neoplasias Gástricas/prevención & control , Anciano , Femenino , Estudios de Seguimiento , Gastritis/complicaciones , Gastritis/diagnóstico , Helicobacter pylori/efectos de los fármacos , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Lesiones Precancerosas/complicaciones , Lesiones Precancerosas/microbiología , Lesiones Precancerosas/prevención & control , Estómago/efectos de los fármacos , Estómago/patología , Estómago/cirugía , Neoplasias Gástricas/complicaciones , Neoplasias Gástricas/cirugía , Resultado del TratamientoRESUMEN
A longitudinal cohort study was conducted in Helicobactor pylori-infected middle-aged Japanese males to evaluate the preventive effects of H. pylori eradication on the development of gastric cancer according to the extent of chronic atrophic gastritis (CAG). The extent of CAG was monitored by baseline serum pepsinogen (PG) levels. We followed 3,656 subjects with persistent H. pylori infection and 473 subjects with successful H. pylori eradication for cancer development for a mean (SD) of 9.3 (0.7) years. Groups with and without extensive CAG were categorized based on PG test-positive criteria to detect extensive CAG of PG I Asunto(s)
Gastritis Atrófica/sangre
, Gastritis Atrófica/microbiología
, Infecciones por Helicobacter/tratamiento farmacológico
, Helicobacter pylori/patogenicidad
, Pepsinógeno A/sangre
, Neoplasias Gástricas/prevención & control
, Anciano
, Estudios de Cohortes
, Femenino
, Gastritis Atrófica/patología
, Infecciones por Helicobacter/diagnóstico
, Humanos
, Estudios Longitudinales
, Masculino
, Persona de Mediana Edad
, Pronóstico
, Factores de Riesgo
, Neoplasias Gástricas/sangre
, Neoplasias Gástricas/diagnóstico
, Tasa de Supervivencia
RESUMEN
A total of 5,209 asymptomatic, middle-aged subjects, whose serum pepsinogen (PG) and Helicobacter pylori antibody levels had been assessed, were followed for 10 years. Subjects with positive serum H. pylori antibodies (>50 U/mL) had an increased cancer risk (HR = 3.48, 95% CI = 1.26-9.64). Risk of gastric cancer increased as the antibody level increased; the H. pylori-positive group with antibody levels >500 U/mL had the highest incidence rate (325/100,000 person-years). Cancer development also increased with a reduced serum PG I level or a reduced PG I/II ratio; the risk was significantly elevated with serum PG I level
Asunto(s)
Anticuerpos Antibacterianos/sangre , Infecciones por Helicobacter/sangre , Infecciones por Helicobacter/epidemiología , Helicobacter pylori/aislamiento & purificación , Pepsinógeno A/sangre , Neoplasias Gástricas/sangre , Neoplasias Gástricas/epidemiología , Adulto , Estudios de Cohortes , Infecciones por Helicobacter/enzimología , Helicobacter pylori/inmunología , Humanos , Japón/epidemiología , Estudios Longitudinales , Persona de Mediana Edad , Factores de Riesgo , Neoplasias Gástricas/enzimología , Neoplasias Gástricas/microbiologíaRESUMEN
BACKGROUND: Gastric cancer screening using the pepsinogen filter test is receiving wide recognition in Japan owing to convenience, freedom from discomfort or risk, efficiency, and economy. Because the long-term outcomes of cancer development in extensive atrophic gastritis detected by pepsinogen test are unclear, test-positive and test-negative subjects were investigated in a longitudinal cohort study. METHODS: Subjects comprised 5,209 middle-aged men with measured serum pepsinogen levels who were followed for 10 years. Cancer development based on "atrophy-positive" and "atrophy-negative" criteria used for cancer screening was investigated. RESULTS: During the study, 63 cases of cancer developed in the cohort, representing an incidence rate of 125 per 100,000 person-years. Pepsinogen test screening using the most widely used atrophy-positive criterion (pepsinogen I, < or =70 ng/mL; pepsinogen I/II ratio, < or =3.0) displayed 58.7% sensitivity, 73.4% specificity, and 2.6% positive predictive value. Cancer incidence rate was 276 per 100,000 person-years for the atrophy-positive group and 70 per 100,000 person-years for the atrophy-negative group. Incidence rate was higher in groups fulfilling stricter positive criteria detecting more extensive atrophy, reaching 424 per 100,000 person-years. In addition, 9.2% of atrophy-negative subjects with pepsinogen I of >70 ng/mL and pepsinogen I/II ratio of < or =3.0 (reflecting putative inflammation-based high pepsinogen II level) are at high risk for cancer, particularly diffuse-type cancer, with a cancer incidence rate comparable with atrophy-positive subjects (216 per 100,000 person-years). CONCLUSION: Atrophy-positive subjects by pepsinogen filter test, particularly those fulfilling stricter criteria, and atrophy-negative subjects with low pepsinogen I/II ratio reflecting putative extensive active inflammation constitute populations at high risk for gastric cancer, requiring thorough endoscopic examination.
Asunto(s)
Tamizaje Masivo/métodos , Pepsinógeno A/sangre , Neoplasias Gástricas/sangre , Adulto , Atrofia/clasificación , Biomarcadores de Tumor , Estudios de Seguimiento , Humanos , Incidencia , Japón/epidemiología , Masculino , Tamizaje Masivo/estadística & datos numéricos , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Factores de Riesgo , Neoplasias Gástricas/epidemiología , Neoplasias Gástricas/patologíaRESUMEN
Since the 1990's, the test for serum pepsinogen as a marker for chronic atrophic gastritis has been incorporated into gastric cancer screening programs, on a trial basis, to identify people at high risk for gastric cancer. The addition of the serum test to the cancer screening program has been shown to improve the detection rate of cancer and pepsinogen testing is useful in detecting early-stage gastric cancers arising from atrophic gastric mucosa, which macroscopically tend to be elevated and histologically differentiated. Furthermore, the cost for the detection of a single cancer case is much less than that for conventional screening. Thus, with the introduction of pepsinogen testing, complimenting barium X-ray, a more efficient screening system is available.
Asunto(s)
Tamizaje Masivo/métodos , Pepsinógeno A/sangre , Neoplasias Gástricas/sangre , Neoplasias Gástricas/diagnóstico , Adulto , Radioisótopos de Bario , Biomarcadores/sangre , Endoscopía Gastrointestinal , Humanos , Incidencia , Japón/epidemiología , Masculino , Tamizaje Masivo/estadística & datos numéricos , Persona de Mediana Edad , Intensificación de Imagen Radiográfica , Medición de Riesgo/métodos , Sensibilidad y Especificidad , Neoplasias Gástricas/epidemiologíaRESUMEN
With the aim of developing more efficient gastric cancer screening programs for use in Japan, we studied a new screening program that combines serum pepsinogen (PG) testing and barium digital radiography (DR). A total of 17 647 middle-aged male subjects underwent workplace screening over a 7-year period using a combination of PG testing and DR. This program's effectiveness, as well as other characteristics of the program, was analyzed. Forty-nine cases of gastric cancer were detected (comprising 88% early cancer cases). The detection rate was 0.28%, and the positive predictive value was 0.85%. The PG test detected 63.3% of cases, DR detected 69.4% of cases, and both tests were positive in 32.7% of cancer cases. The two methods were almost equally effective, and were considerably more effective than conventional screening using photofluorography. Each screening method detected a distinct gastric cancer subgroup; the PG test efficiently detected asymptomatic small early cancer with intestinal type histology, while DR was efficient at detecting cancers with depressed or ulcerated morphology and diffuse type histology. The cost for the detection of a single cancer was much less than that for conventional screening. In fact, it is possible to further reduce the cost of detecting a single cancer to a cost comparable to that of surgically resecting a single gastric cancer. Thus, it is probable that a highly efficient gastric cancer screening system can be implemented by combining the two screening methods. Such a screening program would be beneficial in a population at high risk for gastric cancer.